Objective: To assess the efficacy and safety of catheter ablation (CA) compared with antiarrhythmic drugs (AADs) as first-line treatment for symptomatic paroxysmal atrial fibrillation (AF).
Methods: Systematic review and meta-analysis of randomised controlled trials identified using MEDLINE, Cochrane Library and Embase published between 01/01/2000 and 19/03/2021. The primary efficacy endpoint was the first documented recurrence of atrial arrhythmias following the blanking period. The primary safety endpoint was a composite of all serious adverse events (SAEs).
Results: From 441 records, 6 studies met the inclusion criteria. 609 patients received CA, while 603 received AAD therapy. 212/609 patients in the CA group had a recurrence of atrial arrhythmias as compared with 318/603 in the AADs group resulting in a 36% relative risk reduction (risk ratio: 0.64, 95% CI 0.51 to 0.80, p<0.01). The risk of all SAEs was not statistically different between CA and AAD (0.87, 0.58 to 1.30, p=0.49); 107/609 SAE in the CA group vs 126/603 in the AAD group. Both recurrence of symptomatic atrial arrhythmias (109/505 vs 186/504) and healthcare utilisation (126/397 vs 185/394) were significantly lower in the CA group (0.53, 0.35 to 0.79 and 0.65, 0.48 to 0.89, respectively). There was a 79% reduction in the crossover rate during follow-up among patients randomised to CA compared with AAD (0.21, 0.13 to 0.32, p<0.01).
Conclusions: First-line treatment with CA is superior to AAD therapy in patients with symptomatic paroxysmal AF, as it significantly reduces the recurrence of any atrial arrhythmias and symptomatic atrial arrhythmias, and healthcare resource utilisation with comparable safety profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/heartjnl-2021-319496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Convergent procedure for long-standing persistent atrial fibrillation in heart failure with reduced ejection fraction.
Arch Cardiovasc Dis
December 2024
Service de cardiologie, hôpital Henri-Mondor, 94000 Créteil, France. Electronic address:
Background: Catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction is associated with a significant reduction in morbimortality. The convergent procedure is a valid ablation option for the treatment of long-standing persistent atrial fibrillation.
Aim: To describe the outcomes of patients with heart failure with reduced ejection fraction and long-standing persistent atrial fibrillation who underwent the convergent procedure.
Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
Cleve Clin J Med
January 2025
Tulane Research Innovation for Arrhythmia Discovery, Tulane University School of Medicine, New Orleans, LA.
More and more patients with atrial fibrillation are undergoing catheter ablation as a rhythm-control strategy, but the recurrence rate after the procedure is high. A wide array of risk factors contribute to the pathogenesis of atrial fibrillation, including hypertension, diabetes mellitus, dyslipidemia, obesity, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease (MASLD), smoking, alcohol consumption, and physical inactivity. This review summarizes the emerging evidence for periablation risk-factor modification to optimize postablation outcomes.
View Article and Find Full Text PDFMultiple vascular complications after catheter ablation - successful treatment of pseudoaneurysm and segmental deep vein thrombosis: Case report.
Kardiol Pol
January 2025
1st Chair and Department of Cardiology, Medical University of Warsaw, Warszawa, Poland.
Incidence, Characteristics and Prognostic Significance of Early Recurrences Following Different Ablation Approaches for Persistent Atrial Fibrillation.
Heart Rhythm
December 2024
University of Melbourne, Melbourne, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Victoria, Australia; Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia. Electronic address:
Background: Early recurrence of atrial tachyarrhythmia (ERAT) is common following catheter ablation of atrial fibrillation (AF). The specific clinical and arrhythmia characteristics of ERAT influencing late recurrence risk in persistent AF is unclear. Additionally, the impact of different ablation strategies on the incidence and prognostic significance of ERAT remains unknown.
View Article and Find Full Text PDF12 lead surface ECGs as a surrogate of atrial electrical remodeling - a deep learning based approach.
J Electrocardiol
December 2024
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA; Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.
Background And Purpose: Atrial fibrillation (AF), a common arrhythmia, is linked with atrial electrical and structural changes, notably low voltage areas (LVAs) which are associated with poor ablation outcomes and increased thromboembolic risk. This study aims to evaluate the efficacy of a deep learning model applied to 12‑lead ECGs for non-invasively predicting the presence of LVAs, potentially guiding pre-ablation strategies and improving patient outcomes.
Methods: A retrospective analysis was conducted on 204 AF patients, who underwent catheter ablation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!